In human prostate cancer, PTEN loss is an early tumorigenic lesion, while Wnt-pathway activation through aberrations in APC, CTNNB1, RNF43, and RSPO2 are found in metastatic castration-resistant cancer, suggesting they are associated with tumor progression [31,32]. This evidence concerns the gene PTEN and prostate cancer.